Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy
A phase 2 study evaluated UCB infusion for elderly AML patients, with inclusion criteria including age ≥60, ECOG 0-2, eGFR ≥60, and CR after 1-2 cycles of induction therapy. Exclusions included APL, sAML, HIV/HBV/HCV, and uncontrolled infections. Treatment involved decitabine, cytarabine, and UCB infusion. Primary endpoint was OS; secondary included EFS, MRD, AEs, and recovery times. Safety analyses monitored AEs, with grade 3-4 defined as severe. Single-cell sequencing analyzed pre- and post-UCB infusion samples for biological characteristics.
Beyond basics
The $134 billion U.S. generic drug industry is diversifying beyond standard generics to boost profits, with companies emphasizing niche products, complex pharmaceuticals, biosimilars, and patient services. Unichem, Amneal, and Somerset Pharma are among those expanding their portfolios and manufacturing capabilities to better respond to market needs and supply challenges. Biosimilars, though costly to develop, offer significant rewards and savings, with companies like Amneal and Dr. Reddy's focusing on this segment.
New CPX-351 Data Underscore Complexity of Treating AML in Older Patients
Phase 2 data on CPX-351 in older patients with secondary or high-risk AML showed 49% achieved CR or CRi, with 67% MRD negativity. Median EFS was 3.0 months and OS 7.4 months. Early mortality was higher than in phase 3 trials, and fewer underwent allo-HSCT, possibly due to protocol restrictions and the COVID-19 pandemic. These findings suggest CPX-351's efficacy but highlight the need for better therapies for certain subgroups.
Q&A: A Closer Look at the Current State of Biosimilars in the Drug Market
Biosimilars, introduced in 2015, are complex alternatives to biologics with similar protein structures, offering potential cost savings. Despite initial pricing misalignment, biosimilars' prices have decreased, benefiting patients. MMIT focuses on real-world data and market insights to support biosimilar dispensing.
Efficacy and safety of the combination of decitabine and CHAG priming regimen in the
The study evaluates decitabine combined with CHAG regimen for R/R AML, achieving CR in 74.2% and ORR of 82.2% with fewer side effects. Median RFS was 4.3 months and median OS was 7.75 months. The regimen showed deeper remissions, especially in patients with WT1 gene positivity, AML1-ETO fusion gene positivity, and NPM1 mutation. The study suggests a new treatment option for R/R AML but acknowledges limitations due to its single-center, retrospective nature and short observation time.
Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma
Iris Isufi, MD, discussed NCCN Guidelines for advanced classical Hodgkin lymphoma, recommending ABVD, brentuximab vedotin plus AVD, BrECADD, and nivolumab plus AVD. ABVD has an 80% cure rate but risks bleomycin-induced toxicity. Brentuximab vedotin plus AVD improved overall survival and reduced disease-related deaths. BrECADD showed high progression-free survival and lower treatment-related morbidity. Nivolumab plus AVD had better tolerability and survival outcomes, potentially becoming a standard therapy.
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus ...
Studies on treatments for multiple myeloma include lenalidomide, bortezomib, and dexamethasone with transplantation, EHA-ESMO guidelines, consensus approaches for autologous stem cell transplantation, high-dose chemotherapy with treosulfan and melphalan, adding bendamustine to melphalan before ASCT, and the role of hematopoietic stem cell transplantation.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath